The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 8, 2016, Pages 747-763

  Falagas, Matthew E ^a,b,c   Mavroudis, Andreas D ^a,d   Vardakas, Konstantinos Z ^a,b  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Health Headquarters   (Greece)

Author keywords

antibiotics; clinical trials; Extensively drug resistant (XDR) gram negative; in vitro in vivo activity; lactamases

Indexed keywords

AVIBACTAM; AZTREONAM; BAL 30072; BETA LACTAM ANTIBIOTIC; CEFTAROLINE; CILASTATIN PLUS IMIPENEM; ERAVACYCLINE; FINAFLOXACIN; MEROPENEM PLUS VABORBACTAM; PLAZOMICIN; RELEBACTAM; S 649266; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; DISEASE MODEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG PENETRATION; DRUG RESPONSE; DRUG SAFETY; DRUG TISSUE LEVEL; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACODYNAMICS; REVIEW; TREATMENT OUTCOME; ANIMAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84978763327     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2016.1204911     Document Type: Review

References (113)

1. K.Z.Vardakas, P.I.Rafailidis, A.A.Konstantelias, et al. Predictors of mortality in patients with infections due to multi-drug resistant gram negative bacteria: the study, the patient, the bug or the drug? J Infect. 2013;66(5):401–414.
2. M.E.Falagas, E.K.Vouloumanou, G.Samonis, et al. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–347.
3. M.E.Falagas, K.Z.Vardakas, N.S.Roussos Trimethoprim/sulfamethoxazole for Acinetobacter spp.: a review of current microbiological and clinical evidence. Int J Antimicrob Agents. 2015;46(3):231–241.
4. M.E.Falagas, K.Z.Vardakas, A.Kapaskelis, et al. Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents. 2015;45(5):455–460.
5. M.E.Falagas, G.S.Tansarli, K.Ikawa, et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56(2):272–282.
6. M.E.Falagas, G.S.Tansarli, A.Kapaskelis, et al. Ertapenem use and antimicrobial resistance to group 2 carbapenems in gram-negative infections: a systematic review. Expert Rev Anti Infect Ther. 2013;11(1):69–78.
7. M.E.Falagas, G.S.Tansarli, P.I.Rafailidis, et al. Impact of antibiotic MIC on infection outcome in patients with susceptible gram-negative bacteria: a systematic review and meta-analysis. Antimicrob Agents Chemother. 2012;56(8):4214–4222.
8. M.E.Falagas, K.N.Fragoulis, I.Karydis. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. PLoS One. 2006;1:e11.
9. E.Sukkar. Why are there so few antibiotics in the research and development pipeline? Pharm J. 2013;291:520.
10. A.-P.Magiorakos, A.Srinivasan, R.B.Carey, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
11. Antibiotics currently in clinical development. 2015 [cited 8Jun 2016]. Available from: http://www.pewtrusts.org/~/media/assets/2015/12/antibiotics_datatable_201512.pdf?la=en
12. A.Lapuebla, M.Abdallah, O.Olafisoye, et al. Activity of imipenem with relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother. 2015;59(8):5029–5031.
13. 781. In vitro antibacterial activity of meropenem/RPX7009, (a carbapenem/β-lactamase inhibitor combination) against contemporary Enterobacteriaceae (ENT) isolated from intra-abdominal (IAI) and urinary tract infections (UTI) in the United States (USA). ID Week; 2015 Oct 7–11; San Diego, CA.• Relebactam potentiated imipenem against both MDR K. pneumoniae and P. aeruginosa.
14. H.S.Sader, R.K.Flamm, R.N.Jones. Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010–2011. Antimicrob Agents Chemother. 2013;57(4):1982–1988.
15. J.A.Karlowsky, H.J.Adam, M.R.Baxter, et al. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Antimicrob Agents Chemother. 2013;57(11):5600–5611.
16. R.Testa, R.Cantón, T.Giani, et al. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European gram-negative and gram-positive clinical isolates. Int J Antimicrob Agents. 2015;45(6):641–646.
17. M.Castanheira, G.Williams, R.N.Jones, et al. Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying beta-lactamases prevalent in the United States. Microb Drug Resist. 2014;20(5):436–440.
18. A.Yoshizumi, Y.Ishii, K.Aoki, et al. In vitro susceptibility of characterized beta-lactamase-producing gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations. J Infect Chemother. 2015;21(2):148–151.
19. D.J.Biedenbach, K.Kazmierczak, S.K.Bouchillon, et al. In vitro activity of aztreonam-avibactam against a global collection of gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother. 2015;59(7):4239–4248.
20. X.Wang, F.Zhang, C.Zhao, et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother. 2014;58(3):1774–1778.
21. M.G.Page, C.Dantier, E.Desarbre. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother. 2010;54(6):2291–2302.•• Superior in vitro activity of BAL30072 compared to β-lactams and polymyxin B against MDR A. baumannii.
22. N.Kohira, J.West, A.Ito, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 2016;60(2):729–734.
23. 252. S-649266, a novel siderophore cephalosporin: in vitro activity against gram-negative bacteria including multidrug-resistant strains. ID Week; 2014 Oct 8–12; Philadelphia, PA.• Superior in vitro activity of S-649266 compared to meropenem, cefepime, and piperacillin/tazobactam against both MDR P. aeruginosa and A. baumannii.
24. I.Galani, M.Souli, G.L.Daikos, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother. 2012;24(4):191–194.• Superior in vitro activity of plazomicin than aminoglycoside comparators against MDR, XDR, and PDR Enterobacteriaceae isolates.
25. J.B.Aggen, E.S.Armstrong, A.A.Goldblum, et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother. 2010;54(11):4636–4642.
26. A.Walkty, H.Adam, M.Baxter, et al. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob Agents Chemother. 2014;58(5):2554–2563.
27. W.Stubbings, P.Leow, G.C.Yong, et al. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions. Antimicrob Agents Chemother. 2011;55(9):4394–4397.
28. J.A.Sutcliffe, W.O’Brien, C.Fyfe, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57(11):5548–5558.•• Eravacycline demonstrates ≥twofold more potency in vitro compared to tigecycline against certain Enterobacteriaceae and MDR A. baumannii strains.
29. M.Abdallah, O.Olafisoye, C.Cortes, et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015;59(3):1802–1805.
30. H.Li, M.Estabrook, G.A.Jacoby, et al. In vitro susceptibility of characterized beta-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother. 2015;59(3):1789–1793.
31. A.Lapuebla, M.Abdallah, O.Olafisoye, et al. Activity of meropenem combined with RPX7009, a novel beta-lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother. 2015;59(8):4856–4860.
32. #257. In vitro activity of meropenem/RPX7009, a carbapenem/β-lactamase inhibitor combination tested against contemporary populations of Enterobacteriaceae and KPC-producing strains. ID Week; 2014 Oct 8–12; Philadelphia, PA.
33. S.Vasoo, S.A.Cunningham, N.C.Cole, et al. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli. Antimicrob Agents Chemother. 2015;59(12):7842–7846.
34. S.Mushtaq, N.Woodford, R.Hope, et al. Activity of BAL30072 alone or combined with beta-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. J Antimicrob Chemother. 2013;68(7):1601–1608.
35. D.M.Livermore, M.Warner, S.Mushtaq. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68(10):2286–2290.
36. Activity of aztreonam combined with the beta-lactamase inhibitor avibactam against metallo-β-lactamase-producing organisms [cited 2016 8Jun]. Available from: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=9735
37. D.M.Livermore, S.Mushtaq, M.Warner, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011;66(1):48–53.
38. M.Castanheira, H.S.Sader, D.J.Farrell, et al. Activity of ceftaroline-avibactam tested against gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob Agents Chemother. 2012;56(9):4779–4785.
39. D.Landman, M.Singh, B.El-Imad, et al. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary gram-negative pathogens from New York City, including multidrug-resistant isolates. Int J Antimicrob Agents. 2014;43(6):527–532.
40. R.Almaghrabi, C.J.Clancy, Y.Doi, et al. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother. 2014;58(8):4443–4451.
41. B.Hofer, C.Dantier, K.Gebhardt, et al. Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant gram-negative bacilli. J Antimicrob Chemother. 2013;68(5):1120–1129.
42. P.G.Higgins, D.Stefanik, M.G.Page, et al. In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. J Antimicrob Chemother. 2012;67(5):1167–1169.
43. T.A.Russo, M.G.Page, J.M.Beanan, et al. In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii. J Antimicrob Chemother. 2011;66(4):867–873.
44. D.Landman, P.Kelly, M.Bäcker, et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother. 2011;66(2):332–334.
45. C.García-Salguero, I.Rodríguez-Avial, J.J.Picazo, et al. Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii? Antimicrob Agents Chemother. 2015;59(10):5959–5966.
46. P.G.Higgins, W.Stubbings, H.Wisplinghoff, et al. Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates. Antimicrob Agents Chemother. 2010;54(4):1613–1615.
47. M.J.Pucci, K.Bush. Investigational antimicrobial agents of 2013. Clin Microbiol Rev. 2013;26(4):792–821.
48. S.M.Drawz, K.M.Papp-Wallace, R.A.Bonomo. New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother. 2014;58(4):1835–1846.
49. A-1028. Intrapulmonary pharmacokinetics of MK-7655, a novel β-lactamase inhibitor, dosed in combination with imipenem/cilastatin in healthy subjects. 53rd ICAAC; 2013 Sep 10–13; Denver.
50. Pharmacokinetics of MK-7655, a novel beta-lactamase inhibitor (BLI) in combination with imipenem/cilastatin (IPM/CIL) in subjects with impaired renal function. 2013 [cited 2016 24Mar]. Available from: http://www.icaaconline.com/php/icaac2013abstracts/data/papers/2012/A/2012_A-010.htm
51. E.Mavridou, R.J.Melchers, A.C.Van Mil, et al. Pharmacodynamics of imipenem in combination with beta-lactamase inhibitor MK7655 in a murine thigh model. Antimicrob Agents Chemother. 2015;59(2):790–795.
52. F-259. A phase 2 study to evaluate the efficacy & safety of relebactam (REL) + imipenem/cilastatin (IMI) vs IMI alone in subjects with complicated intra-abdominal infection (cIAI). 55thICAAC; 2015 Sep 17–21; San Diego, CA.
53. Efficacy and safety of imipenem+cilastatin/relebactam (MK-7655A) versus colistimethate sodium + imipenem+cilastatin in imipenem-resistant bacterial infection (MK-7655A-013) (RESTORE-IMI 1). 2016 [cited 2016 8Jun]. Available from: https://clinicaltrials.gov/ct2/show/NCT02452047•• Efficacy and safety of imipenem–cilastatin/relebactam compared to imipenem–cilastatin/colistimethate sodium combination.
54. Imipenem/relebactam/cilastatin versus piperacillin/tazobactam for treatment of participants with bacterial pneumonia (MK-7655A-014) (RESTORE-IMI 2). 2016 [cited 2016 8Jun]. Available from: https://clinicaltrials.gov/ct2/show/NCT02493764
55. E.Wenzler, M.H.Gotfried, J.S.Loutit, et al. Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. Antimicrob Agents Chemother. 2015;59(12):7232–7239.
56. A phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor RPX7009 alone, meropenem alone, and both in combination (carbavance) TID for 7 days in healthy adult subjects. 2014 [cited 2016 8Jun]. Available from: http://ofid.oxfordjournals.org/content/1/suppl_1/S154.full
57. F-958. In vivo efficacy of carbavance (meropenem/RPX7009) against KPC-producing Enterobacteriaceae. 54th ICAAC; 2014 Sep 5–9; Washington, DC.
58. Efficacy, safety, tolerability of carbavance compared to piperacillin/tazobactam in cUTIs, including AP, in adults. 2016 [cited 2016 8Jun]. Available from: https://clinicaltrials.gov/ct2/show/NCT02166476
59. The medicines company announces first patient enrollment in phase 3 studies of CARBAVANCE™ in development for the treatment of serious bacterial infections due to gram-negative bacteria. 2014 [cited 2016 8Jun]. Available from: http://ir.themedicinescompany.com/mobile.view?c=122204&v=203&d=1&id=1985873
60. Efficacy, safety, tolerability of carbavance compared to best available therapy in serious infections due to carbapenem resistant enterobacteriaceae, in adults. 2016 [cited 2016 8Jun]. Available from: https://clinicaltrials.gov/ct2/show/NCT02168946•• Meropenem/vaborbactam is compared to the best available therapy in subjects with serious infections caused by carbapenem-resistant Enterobacteriaceae.
61. D.A.Shirley, E.L.Heil, J.K.Johnson. Ceftaroline fosamil: a brief clinical review. Infect Dis Ther. 2013;2(2):95–110.
62. R.J.Ghamrawi, E.Neuner, S.J.Rehm. Ceftaroline fosamil: a super-cephalosporin? Cleve Clin J Med. 2015;82(7):437–444.
63. N.P.Krishnan, N.Q.Nguyen, K.M.Papp-Wallace, et al. Inhibition of klebsiella beta-lactamases (SHV-1 and KPC-2) by avibactam: a structural study. PLoS One. 2015;10(9):e0136813.
64. T.A.Riccobene, S.F.Su, D.Rank. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Antimicrob Agents Chemother. 2013;57(3):1496–1504.
65. M.-U.Rashid, S.Rosenborg, G.Panagiotidis, et al. Ecological effect of ceftaroline-avibactam on the normal human intestinal microbiota. Antimicrob Agents Chemother. 2015;59(8):4504–4509.
66. D.E.Wiskirchen, J.L.Crandon, G.H.Furtado, et al. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55(7):3220–3225.
67. A.A.Bhalodi, J.L.Crandon, G.Williams, et al. In vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection model. Antimicrob Agents Chemother. 2013;57(11):5674–5678.
68. Comparative study of coadministered ceftaroline fosamil and NXL104 vs. intravenous doripenem in adult subjects with complicated urinary tract infections. 2014 [cited 2016 8Jun]. Available from: https://clinicaltrials.gov/ct2/show/NCT01281462?term=ceftaroline+avibactam&rank=2
69. Aztreonam. 2015 [cited 2016 8Jun]. Available from: http://www.drugs.com/pro/aztreonam.html
70. J.L.Crandon, D.P.Nicolau. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-beta-lactamase producers. Antimicrob Agents Chemother. 2013;57(7):3299–3306.
71. Determine the PK and safety and tolerability of ATM-AVI for the treatment of ciais in hospitalized adults (REJUVENATE). 2016 [cited 2016 8Jun]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02655419
72. F-1563. S-649266, a novel siderophore cephalosporin: II. Impact of active transport via iron regulated outer membrane proteins on resistance selection. 54th ICAAC; 2014 Sep 5–9; Washington, DC.
73. P0254. S-649266 dose adjustment for patients with impaired renal function [cited 2016 8Jun]. Available from: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=22724
74. S-649266, a novel cephalosporin for gram negative bacterial infection: pharmacokinetics (PK), safety and tolerability in healthy subjects. 54th ICAAC; 2014 Sep 5–9; Washington, DC.
75. F-1558. S-649266, a nover siderophore cephalosporin: IV. In vivo efficacy in various murine infection models. 54th ICAAC; 2014 Sep 5–9; Washington, DC.
76. A study of efficacy/safety of intravenous S-649266 versus imipenem/cilastatin in complicated urinary tract infections. 2016 [cited 2016 8Jun]. Available from: https://clinicaltrials.gov/ct2/show/NCT02321800
77. Study of S-649266 or best available therapy for the treatment of severe infections caused by carbapenem-resistant gram-negative pathogens. 2016 [cited 2016 8Jun]. Available from: https://clinicaltrials.gov/ct2/show/NCT02714595
78. A2-572. Pharmacokinetics and safety of the novel sulfactam antibiotic BAL30072 after single ascending dose infusions in healthy volunteers. 53rd ICAAC; 2013 Sep 10–13; Denver, CO.
79. P908. Efficacy of BAL30072 in murine thigh infection models of multi-resistant gram-negative bacteria. 23rd ECCMID; 2013 Apr 27–30; Berlin.
80. ECCMID-1376. Efficacy of BAL30072 in murine lung infection models of multi-resistant gram-negative bacteria [cited 2016 9Jun]. Available from: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=25497
81. ECCMID-1381. Efficacy of BAL30072 in combination with meropenem in murine thigh infection models of multi-resistant gram-negative bacteria [cited 2016 9Jun]. Available from: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=27236
82. Basilea initiates phase 1 combination study with its gram-negative antibiotic BAL30072 and meropenem. 2014 [cited 2016 9 Jun]. Available from: http://www.basilea.com/Investor-Relations/News-and-Media/Basilea-initiates-phase-1-combination-study-with-its-Gram-negative-antibiotic-BAL30072-and-meropenem/b9d97fd2-d4ae-16ad-8a09-1faa146732ba/
83. BAL30072. Basilea pharmaceutica. 2016 [cited 2016 9Jun]. Available from: http://www.basilea.com/Portfolio/BAL30072/
84. G.G.Zhanel, C.D.Lawson, S.Zelenitsky, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther. 2012;10(4):459–473.
85. P-1637. A double-blind, randomized, placebo-controlled study to assess the safety, tolerability, plasma pharmacokinetics and lung penetration of intravenous plazomicin in healthy subjects. 23rd ECCMID; 2013 Apr 27–30; Berlin.
86. R.T.Cass, C.D.Brooks, N.A.Havrilla, et al. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother. 2011;55(12):5874–5880.
87. ACHAOGEN: developing novel antibacterials to treat multi-drug resistant gram-negative bacterial infections. 2014 [cited 2016 9Jun]. Available from: http://files.shareholder.com/downloads/AMDA-2JY46Z/0x0x741737/5655c063-d9e6-4cb0-b114-c5b7af268ff3/Achaogen%20-%20Needham%20Healthcare%20Conf%20-%202014-04-08%20FINAL.pdf
88. P-918. The pharmacokinetics (PK) and safety of plazomicin in subjects with renal impairment. 23rd ECCMID; 2013 Apr 27–30; Berlin.
89. N.Reyes, J.B.Aggen, C.F.Kostrub. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. Antimicrob Agents Chemother. 2011;55(4):1728–1733.
90. Achaogen announces all objectives met in phase 2 plazomicin complicated urinary tract infections study and start of first-in-human study with ACHN-975. 2012 [cited 2016 9Jun]. Available from: http://www.achaogen.com/media-all/2012/5/15/achaogen-announces-all-objectives-met-in-phase-2-plazomicin-complicated-urinary-tract-infections-study-and-start-of-first-in-human-study-with-achn-975
91. A study of plazomicin compared with colistin in patients with infection due to carbapenem-resistant Enterobacteriaceae (CRE) (CARE). 2016 [cited 2016 9Jun]. Available from: https://clinicaltrials.gov/ct2/show/NCT01970371
92. A study of plazomicin compared with meropenem for the treatment of complicated urinary tract infection (cUTI) including acute pyelonephritis (AP). 2016 [cited 2016 9Jun]. Available from: https://clinicaltrials.gov/ct2/show/NCT02486627
93. (8th January 2015) finafloxacin background (phase II cUTI trial & drug characteristics). 2015 [cited 2016 9Jun]. Available from: http://www.merlionpharma.com/?q=node/228
94. H.Patel, A.Andresen, A.Vente, et al. Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 2011;55(9):4386–4393.
95. E-1835. Investigation of in vitro antagonistic and synergistic effects of finafloxacin in combination with other antibiotics. 51th ICAAC; 2011 Sep 17–20; Chicago.
96. F1-2045. In vivo efficacy of finafloxacin in difficult to treat animal models of infection. 48th ICAAC/46TH IDSA; 2008 Oct 25–28; Washington (DC).
97. L-1251. Safety and efficacy of finafloxacin versus ciprofloxacin (CPX) in the treatment of hospitalized patients with complicated urinary tract infections (cUTI) and pyelonephritis (PN) determined in a phase 2 clinical study, 2015. 55th ICAAC; 2015 Sep 17–21; San Diego, CA.
98. Finafloxacin 300 mg twice a day (b.i.d.) versus ciprofloxacin 250 mg twice a day (b.i.d) in patients with lower uncomplicated UTI (uUTI) (FLUT). 2009 [cited 2016 9Jun]. Available from: https://clinicaltrials.gov/ct2/show/NCT00722735
99. Efficacy and safety study of finafloxacin used in helicobacter pylori infected patients (FLASH). 2009 [cited 2016 9Jun]. Available from: https://clinicaltrials.gov/ct2/show/NCT00723502
100. G.G.Zhanel, D.Cheung, H.Adam, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567–588.
101. T.H.Grossman, A.L.Starosta, C.Fyfe, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012;56(5):2559–2564.
102. K.P.Connors, S.T.Housman, J.S.Pope, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother. 2014;58(4):2113–2118.
103. T.H.Grossman, T.M.Murphy, A.M.Slee, et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015;59(5):2567–2571.
104. J.S.Solomkin, M.K.Ramesh, G.Cesnauskas, et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58(4):1847–1854.
105. Tetraphase announces top-line results from IGNITE2 phase 3 clinical trial of eravacycline in cuti. Tetraphase Pharmaceuticals. 2015 [cited 2016 9Jun]. Available from: http://ir.tphase.com/releasedetail.cfm?releaseid=930613
106. K.Z.Vardakas, P.I.Rafailidis, M.E.Falagas. Effectiveness and safety of tigecycline: focus on use for approved indications. Clin Infect Dis. 2012;54(11):1672–1674.
107. F.Shen, Q.Han, D.Xie, et al. Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Int J Infect Dis. 2015;39:25–33.
108. P.Prasad, J.Sun, R.L.Danner, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54(12):1699–1709.
109. A.Zarkali, D.E.Karageorgopoulos, P.I.Rafailidis, et al. Frequency of the off-label use of monoclonal antibodies in clinical practice: a systematic review of the literature. Curr Med Res Opin. 2014;30(3):471–480.
110. K.Z.Vardakas, F.Ntziora, M.E.Falagas. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother. 2007;8(14):2381–2400.
111. G.S.Tansarli, P.I.Rafailidis, A.Kapaskelis, et al. Frequency of the off-label use of antibiotics in clinical practice: a systematic review. Expert Rev Anti Infect Ther. 2012;10(12):1383–1392.
112. P.I.Rafailidis, I.A.Bliziotis, M.E.Falagas. Case-control studies reporting on risk factors for emergence of antimicrobial resistance: bias associated with the selection of the control group. Microb Drug Resist. 2010;16(4):303–308.
113. M.E.Falagas, P.Kopterides. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect. 2006;64(1):7–15.